Strategic Investment Advisors MI Has $1.19 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Strategic Investment Advisors MI lowered its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 45.4% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 46,998 shares of the biopharmaceutical company's stock after selling 39,033 shares during the period. Strategic Investment Advisors MI's holdings in Pfizer were worth $1,191,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of PFE. Rialto Wealth Management LLC purchased a new stake in Pfizer in the 4th quarter worth approximately $26,000. Clarity Asset Management Inc. acquired a new position in shares of Pfizer in the fourth quarter worth $27,000. Gould Capital LLC raised its holdings in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 493 shares in the last quarter. Kohmann Bosshard Financial Services LLC purchased a new position in Pfizer in the fourth quarter valued at about $28,000. Finally, Bernard Wealth Management Corp. purchased a new position in Pfizer in the fourth quarter valued at about $30,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Stock Performance

PFE stock traded down $0.02 during mid-day trading on Wednesday, reaching $24.29. 25,568,205 shares of the stock traded hands, compared to its average volume of 41,231,216. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. The business has a 50-day moving average of $23.33 and a two-hundred day moving average of $24.87. The firm has a market capitalization of $138.10 billion, a PE ratio of 17.60, a P/E/G ratio of 0.87 and a beta of 0.57. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The firm's revenue for the quarter was down 7.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.82 EPS. As a group, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, June 13th. Investors of record on Friday, May 9th were given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.08%. The ex-dividend date of this dividend was Friday, May 9th. Pfizer's dividend payout ratio (DPR) is currently 124.64%.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Cantor Fitzgerald began coverage on Pfizer in a report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price objective on the stock. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Guggenheim restated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Finally, Citigroup reissued a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $29.17.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.